A growing subpopulation of patients with gout can be characterised as having "difficult gout".[@b1] These patients are often intolerant of, or refractory to, standard therapeutic approaches to gouty inflammation---non-steroidal anti-inflammatory drugs (NSAIDs), systemic or intra-articular glucocorticosteroids, or colchicine.[@b2] Many patients with difficult gout have demonstrated intolerance to, contraindications to, or failure of multiple available urate-lowering treatments.[@b1] [@b3] [@b4] [@b5]

Recent data support an important role for interleukin 1β (IL1β) in the inflammatory process associated with monosodium urate (MSU) crystal deposits in tissues of patients with gout. MSU crystals promote inflammation in large part by inducing activation of the cryopyrin (NLRP3) inflammasome, an intracellular, multiprotein complex responsible for cleavage of caspase-1 that is essential for the processing and secretion of IL1β.[@b6] The release of IL1β[@b7] [@b8] promotes neutrophil influx into the joint that both drives and sustains gouty inflammation.[@b1] A recent, open-label, uncontrolled pilot study of the soluble IL1 receptor antagonist anakinra suggested benefit in refractory human gouty inflammation.[@b9]

Rilonacept, a soluble receptor-Fc fusion protein, engages and inhibits both IL1α and IL1β and has demonstrated rapid and durable effects in a phase 3 study of patients with cryopyrin-associated periodic syndromes, a spectrum of autoinflammatory disorders arising from NLRP3 mutations encoding an aberrant cryopyrin protein and dysregulating the inflammasome.[@b10] The proof-of-concept study reported here explored the potential utility of rilonacept in patients with chronic, inflamed joints in whom standard gout treatments were either contraindicated or failed to alleviate pain and inflammation.

Patients and methods {#s1}
====================

Study objectives {#s1a}
----------------

The primary objective of this proof-of-concept study was to assess the safety of rilonacept in patients with chronic active gouty arthritis. Secondary objectives were to compare changes in self-reported pain scores, in patients' and physicians' global assessments and in levels of high-sensitivity C-reactive protein (hsCRP) during a placebo run-in phase with those during active treatment. Changes in inflammatory pathologies of affected joints with rilonacept treatment were evaluated using a physician-assessment tool designed specifically for this study that takes into account both symptoms and severity in affected joints.

Study design {#s1b}
------------

The study was reviewed and approved by local institutional review boards, consistent with good clinical practice and applicable regulatory requirements. Written consent was obtained from all patients. In this 14-week, multicentre, non-randomised, monosequence crossover study, a 1-week screening period was followed by a single-blind placebo run-in period of 2-weeks' duration (week 0 through the end of week 1). Subsequently, patients entered the active treatment period (week 2 through the end of week 7). A 6-week rilonacept withdrawal period (week 8 through the end of week 13) completed the study.

Study population {#s1c}
----------------

Major inclusion criteria were diagnosis by a doctor of chronic active monoarticular or polyarticular gouty arthritis for at least 6 months, with one or more continuously inflamed joints (self-reported or otherwise) for the 4 or more weeks before screening. Patients had pain scores of ⩾3 on a 0--10 point visual analogue scale (VAS). Diagnosis of gout was based on detection of MSU crystals in the synovial fluid, chronically raised serum urate levels and/or tophi. Standard treatments for gout, hyperuricaemia, flare prophylaxis, or pain had been ineffective or involved risks related to side effects. Patients were men and women at least 18 years of age; women of reproductive age agreed to meet contraception requirements.

Among reasons for exclusion were chronic or active infection (systemic or joint); estimated glomerular filtration rate \<30 ml/min; treatment with a live (attenuated) virus vaccine during the 3 months before study entry; treatment (\<5 half-lives) with an IL1 or a tumour necrosis factor inhibitor; and a history of listeriosis or tuberculosis.

Treatment {#s1d}
---------

After eligibility determinations, patients were screened within 7 days of the start of the study. Day 0 (baseline) to the end of week 1 was the single-blind placebo run-in period. The active treatment period began at week 2 when all patients were switched to receive single-blind rilonacept, beginning with a loading dose of 320 mg (two 2 ml injections) administered subcutaneously, followed by rilonacept 160 mg once a week for weeks 3 through 7 and ended with the post-treatment withdrawal phase beginning at week 8. This dosing regimen has been shown to be well tolerated and efficacious in patients with cryopyrin-associated periodic syndromes, including improvement in joint pains, fever and rash,[@b11] and was felt to offer the possibility of a favourable risk--benefit assessment. [Figure 1](#ard-68-10-1613-f01){ref-type="fig"} presents the study design, including dosing and assessment schedule.

![Study design schematic.](ARD-68-10-1613-f01){#ard-68-10-1613-f01}

Patients were allowed to continue taking their previously prescribed drugs, including aspirin (⩽325 mg/day), NSAIDs (to remain at a stable dose during the trial), allopurinol (if taken for at least 2 months before baseline), probenecid and colchicine (⩽1.2 mg daily, if taken at a stable dose for at least 1 month before baseline).

Safety assessments {#s1e}
------------------

Safety was assessed by monitoring treatment-emergent adverse events (AEs); laboratory values, including anti-rilonacept antibodies; vital signs; chest *x*-ray findings; electrocardiograms; physical examinations; and concomitant drugs. AEs and serious AEs were collected from the time the subject signed the informed consent form through the final study visit.

Efficacy assessments {#s1f}
--------------------

Primary efficacy was determined by patient's pain scores on a 10-point/21-increment VAS which were determined at each visit for the preceding 24 h. Patients were asked to indicate the level of pain they had experienced by filling in a circle on the scale, where "0" was representative of "no pain," and "10" was representative of "severe pain." Additional efficacy end points included patients' and physicians' global assessments; percentage of responders with 50% and 75% improvements in VAS pain scores; and hsCRP levels. To specifically examine joint pathologies, the following mean changes were assessed: (*a*) the number of all affected joints in which at least one of three symptoms or signs (swelling, tenderness, or erythema) were present (1 point/joint); (*b*) symptom-adjusted score (number of symptoms/joint (maximum: 3 points/joint); and (*c*) symptom severity-adjusted score, weighting by severity of each symptom (1, mild; 2, moderate; 3, severe) (maximum: 9 points/joint if the joint was severely swollen, severely tender and severely erythematous).

Data analysis and statistics {#s1g}
----------------------------

Three comparisons were made for each variable assessed: run-in phase or placebo effect, by change from baseline to week 2; active-treatment effect, by change from end of week 2 to end of week 8; and post-treatment phase or withdrawal effect, by change from week 8 to week 14. Continuous variables were analysed using the signed-rank test. Proportions were analysed by comparing the proportion with 10% using a binomial test.

Results {#s2}
=======

Of the 15 patients screened, 10 were enrolled and treated. One patient withdrew owing to an AE. [Table 1](#ard-68-10-1613-t01){ref-type="table"} lists the demographic characteristics of the 10 patients treated.

###### 

Patient (n = 10) demographics and baseline characteristics\*

  Baseline characteristics                     Value
  ---------------------------------------- --------------
  Age at screening (years)                 
      Mean (SD)                             61.5 (10.0)
      Median                                    59.5
      Minimum, maximum                         50, 78
                                           
  Sex, n (%)                               
      Male                                     8 (80)
      Female                                   2 (20)
                                           
  Race, n (%)                              
      Black or African-American                1 (10)
      White                                    9 (90)
                                           
  Ethnicity, n (%)                         
      Non-Hispanic/Latino                     10 (100)
                                           
  Comorbidities at baseline, n (%)         
      Hypertension                            10 (100)
      Obesity                                  8 (80)
      Hyperlipidaemia                          5 (50)
      Other cardiac disorders (CHF, CAD)       3 (30)
      Upper gastrointestinal disorders         2 (20)
      Depression                               2 (20)
      Anxiety                                  2 (20)
      Moderate renal disease†                  2 (20)
      Diabetes                                 1 (10)
                                           
  Duration of gout (years)                 
      Mean                                       13
      Minimum, maximum                         3, 26
                                           
  Tophi in ⩾1 joint, n (%)                     5 (50)
                                           
  Weight (kg)                              
      Mean (SD)                             105.3 (20.0)
      Median                                   107.6
      Minimum, maximum                      62.6, 131.5
                                           
  Height (cm)                              
      Mean (SD)                             171.2 (10.6)
      Median                                   170.2
      Minimum, maximum                      156.3, 187.2

\*All patients treated; †glomerular filtration rate (GFR) 30--59 ml/min; patients with GFR \<30 ml/min were excluded from the study.

CAD, coronary artery disease; CHF, congestive heart failure.

Safety {#s2a}
------

All patients enrolled received all protocol-specified doses of rilonacept, except for one patient who discontinued treatment early. One treated patient, a 50-year-old man, withdrew because of an adverse event after the second week of rilonacept injections owing to severe injection site erythema and induration, both judged to be related to study treatment by the investigator and both resolved without sequelae.

AEs with rilonacept were rare and most often involved the injection site. No deaths and no serious AEs occurred during the study. Vital signs, urine analysis, chemistry, or other laboratory parameters remained without clinically significant changes.

Three patients in this study tested positive for anti-rilonacept antibodies at some time point. All antibody titres were low (⩽1/200) or equal to the minimum required dilution (1/100). The activity of these antibodies was not rilonacept neutralising. No correlation was apparent with any specific AE in patients with anti-rilonacept antibodies and did not appear to affect efficacy.

Efficacy {#s2b}
--------

During the first 2 weeks of the active treatment phase, median patients' self-reported VAS pain scores were significantly reduced from the placebo run-in phase (5.0 to 2.8; p\<0.049) with sustained improvement after 6 weeks of rilonacept treatment (week 8) (1.3; p\<0.049) ([fig 2A](#ard-68-10-1613-f02){ref-type="fig"}). Patients' ([fig 2B](#ard-68-10-1613-f02){ref-type="fig"}) and physicians' median global assessment scores showed a trend towards "feeling well" from the placebo run-in to the end of active treatment (week 8) and shifted back towards "feeling very unwell" during the post-treatment follow-up phase.

![(A) Patient pain visual analogue score (VAS) (median). \*p Value from signed-rank test. Pain scores indicate the level of pain experienced by the patient over the preceding 24 h and reported at a study visit. On a 10-point scale, "0" represented "no pain," and "10" represented "severe pain." (last observation carried forward (LOCF); n = 10). The LOCF was used to assign any missing values. (B) Patient's global assessment score (median). On a 10-point scale, "0" represented normal/none and "10" represented severe; LOCF; n = 10. ^†^Week 2 vs day 0; ^‡^week 8 vs week 2 (see online supplementary text files 1 and 2). (C) Symptom and severity-adjusted joint scores (median). Symptom-severity adjusted joint scores were derived by weighting the joint count by severity (1, mild; 2, moderate; 3, severe) for each symptom (swelling, tenderness and erythema) for each joint for a possible maximum score of 9 per joint. ^†^Week 2 vs day 0; ^‡^week 8 vs week 2. (D) High-sensitivity C-reactive protein (hsCRP) levels (median). Normal limit \<0.287 mg/dl (defined by central laboratory). ^†^Week 2 vs day 0; ^‡^week 8 vs week 2.](ARD-68-10-1613-f02){#ard-68-10-1613-f02}

This short-term treatment with rilonacept had no significant effect on the number of affected joints (online supplementary fig 1). However, when the number and severity of symptoms in all joints were considered, significant differences were seen with rilonacept treatment. The median symptom-adjusted joint scores fell from 7.0 at week 2 (end of placebo run-in) to 2.0 with 6 weeks of treatment (week 8) (p\<0.049) (online supplementary [fig 2](#ard-68-10-1613-f02){ref-type="fig"}), while the symptom severity-adjusted median score for all affected joints also fell significantly, from 8.0 at week 2 baseline to 2.5 at week 8 (p\<0.049) ([fig 2C](#ard-68-10-1613-f02){ref-type="fig"}).

The median symptom-adjusted joint scores and severity-adjusted joint scores were 2.0 and 2.5 at week 8 (end of treatment) and 2.0 and 4.0 at week 14 (after withdrawal of treatment), respectively (online supplementary [fig 2](#ard-68-10-1613-f02){ref-type="fig"} and [fig 2C](#ard-68-10-1613-f02){ref-type="fig"}).

Changes in CRP {#s2c}
--------------

Median hsCRP levels were significantly decreased with rilonacept treatment from 0.4 mg/dl at week 2 (end of placebo run-in) to 0.1, 0.1 and 0.2 mg/dl (p = 0.002, 0.010 and 0.004) at weeks 4, 6 and 8, respectively (normal level \<0.3 mg/dl) ([fig 2D](#ard-68-10-1613-f02){ref-type="fig"}).

Responder analysis {#s2d}
------------------

After 6 weeks of rilonacept treatment, 6/of 10 (60%) patients reported a percentage change in self-reported pain scores that represented at least a 50% improvement (p\<0.001); 5/10 (50%) of patients had at least a 75% improvement with rilonacept (p⩽0.01) ([fig 3](#ard-68-10-1613-f03){ref-type="fig"}).

![(A) Pain responder analysis. Last observation carried forward (LOCF) (n = 10). (B) Pain responder analysis. LOCF (n = 10). \*Week 2 to day 0; \*\*week 4 vs week 2; ^†^week 6 vs week 2; ^‡^week 8 vs week 2.](ARD-68-10-1613-f03){#ard-68-10-1613-f03}

Discussion {#s3}
==========

This pilot study explored the potential utility of inhibition of IL1 in patients with chronic active gout, assessing the safety profile of rilonacept and evaluating changes in disease activity with its use. The study design, which was monosequence crossover and non-randomised, including a single-blind placebo run-in followed by active treatment and subsequent withdrawal period, allowed for this assessment. In this patient population, rilonacept was generally well tolerated. Injection site reactions were the most common AE, usually mild in severity.

Rilonacept administration for 6 weeks also yielded clinical improvements; specifically, a trend towards progressive improvement over time. Patients' self-reported median pain VAS scores steadily and significantly decreased over the course of rilonacept treatment. The majority of patients reported at least a 75% improvement in pain after rilonacept treatment that was not seen after withdrawal of rilonacept; hsCRP levels significantly decreased with treatment. This acute phase reactant change is consistent with evidence correlating circulating levels of CRP with acute gouty attacks.[@b12] Although preliminary, and using a non-validated instrument, symptom-adjusted and severity-adjusted joint scores showed significant improvements with rilonacept treatment. These adjusted scores provided a means to detect significant changes in joint pathologies with treatment.

Consistent with results in a recent safety and pharmacokinetics trial involving patients with end-stage renal disease,[@b13] the dosing of rilonacept in this study was not adjusted in the two patients with moderately impaired kidney function.

The primary limitations of this study were the small cohort size, a short placebo run-in phase and the absence of independent blinded joint assessors. This study also did not directly assess the relative contributions to chronic gouty arthritis of IL1α and IL1β, both of which are inhibited by rilonacept. Despite these limitations, this study demonstrated statistically significant improvement in clinical and laboratory measures of gout.

In conclusion, this proof-of-concept study provided a positive signal to suggest that rilonacept may offer a well-tolerated approach for reducing pain in patients with chronic active difficult gouty arthritis not adequately managed with other treatments. The results further support the hypothesis that IL1 blockade may represent a useful and selective treatment strategy for the growing population of patients with gout, including chronic, refractory gouty arthritis, suggesting that rilonacept should be studied further in patients with gout.
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